The company’s decision to reclaim its Amazon presence from third-party managers in February 2026 yielded immediate results, with revenue from the platform increasing fivefold to $349,000. This growth in digital channels helped e-commerce revenue reach $511,000, surpassing direct business-to-business sales for the first time in company history. Increased adoption of Evolve—the firm’s primary rodent fertility control product—accounted for 86% of total product revenue, reflecting a successful push into professional and consumer markets.
Despite the revenue gains, SenesTech recorded a net loss of $1.8 million, though this figure includes $273,000 in severance costs. CEO Michael Edell, who took the helm in May 2026, is now prioritizing the expansion of the company’s sales team under new executive leadership to capture further market share in agriculture and municipal sectors. With $5.1 million in cash remaining at the end of the quarter, the company is betting on its new AI-enabled assessment services and a revamped website to maintain momentum through the second half of the year.

Comments (0)
No comments yet. Be the first!